Wells Fargo Maintains Overweight on Relay Therapeutics, Raises Price Target to $21

Benzinga Newsdesk www.benzinga.com Positive 83.3%

Neg 0% Neu 0% Pos 83.3%

Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $17 to $21.